Skip to content

CG Oncology CGON Return on equity

Return on equity at other companies

Pfizer logo
PfizerPFE
10.6%
Johnson & Johnson logo
Johnson & JohnsonJNJ
26.4%-3.0pp
Gilead Sciences logo
Gilead SciencesGILD
43.2%+10.7pp
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-85.7%+1.7pp
Tango Therapeutics logo
Tango TherapeuticsTNGX
-38.4%-10.5pp
Celcuity logo
CelcuityCELC
-275.2%-990pp

Other financials

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total debt$7.6M+631%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation

See full
Market cap$5.39B+206%

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Debt / equity0.0×
Current ratio31.3×+0.3×

Where this comes from

Calculated from CG Oncology’s reported figures.

Based on trailing twelve months.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CG Oncology's return on equity?
CG Oncology (CGON) reported return on equity of -20.8% in Q1 2026.
How has CG Oncology's return on equity changed year-over-year?
CG Oncology's return on equity decreased by 25.4% year-over-year, from -16.6% to -20.8%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.